Immune-mediated thrombocytopenia (IMT) is a serious autoimmune disorder in dogs where the immune system mistakenly targets and destroys the blood platelets essential for clotting. Without sufficient platelets, a dog’s blood cannot clot properly, leading to prolonged bleeding during injuries or surgery. This bleeding can result in anaemia and, in severe cases, can become life-threatening.
IMT is an autoimmune condition in which a dog’s immune system creates antibodies that attack its own platelets, causing their destruction either partially or completely. Platelets play a vital role in repairing blood vessels and forming clots to prevent excessive bleeding. Dogs affected by IMT have dangerously low platelet counts, which compromises their ability to heal wounds and control bleeding efficiently.
The causes of IMT can be complex and are classified as either primary or secondary. Primary IMT occurs when the immune system attacks platelets without an identifiable trigger. Secondary IMT develops due to another health issue, such as an infection, cancer, or adverse drug reaction.
Female dogs are more frequently diagnosed with IMT. Secondary causes often include cancers like lymphoma, certain medications (including some antibiotics), viral and bacterial infections, and tick-borne diseases. Due to the wide variety of possible causes, finding the exact trigger can be very challenging.
The symptoms a dog exhibits depend on the severity of the platelet deficiency and any underlying conditions. Common signs include:
Severe cases may involve internal bleeding such as in the brain, resulting in seizures, or bleeding in the chest or abdomen, which can be fatal. Even minor cuts may bleed excessively and fail to stop quickly.
Currently, there is no single definitive test for IMT. Veterinarians primarily diagnose this condition by performing thorough blood tests to confirm low platelet counts and rule out other causes of thrombocytopenia. Sometimes bone marrow evaluations or additional diagnostics may be required to exclude infections or cancers.
Certain breeds tend to have a higher predisposition to primary IMT, including:
Treatment aims to suppress the dog's immune system to prevent platelet destruction, stabilise the dog's condition, and manage symptoms. Key treatment approaches include:
Most dogs (70-90%) respond well to treatment with immunosuppressive drugs and supportive care and can go on to live healthy lives. However, relapses can occur in up to 30% of cases, often within a few months of initial diagnosis, emphasising the importance of regular veterinary check-ups to monitor platelet levels and general health.
Owners must maintain close communication with their vet, watch for signs of bleeding or illness, and use prescribed medications responsibly. Responsible pet ownership includes understanding the severity of IMT, following treatment plans diligently, and providing supportive home care to ensure the best outcomes.
By recognising the signs early and acting swiftly with professional veterinary care, immune-mediated thrombocytopenia can be managed successfully, giving affected dogs the best chance at a good quality of life.